PregnancypUMPreg2NCT07602036
Type 2 Diabetes and Pregnancy a Single-arm Interventional Study
A study testing Automated insulin delivery system - Medtronic 780G in people with Pregnancy and Type 2 Diabetes, run by Poznan University of Medical Sciences at 1 site in Poland.
Trial summary
This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Pregnancy, Type 2 Diabetes
- What is being tested?
- Automated insulin delivery system - Medtronic 780G
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 sitePoland
- Study dates
- 1 May 2026to Feb 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women with diagnosed pregestational type 2 diabetes or HbA1c >6.5% in the 1st trimester (ADA, PTD)
- Age 18-45 years
- Gestational age of 16 weeks +0 days or less at baseline
- Singleton pregnancy
- HbA1c at baseline 5.0-10%
- A viable pregnancy at the recruitment
- Willingness to continue the treatment until delivery in the clinic
Who cannot join
- Other types of diabetes including T1D and Monogenic diabetes
- Major fetal congenital defects
- Severe nephropathy, psychiatric illness or other serious medical disorder that in the judgment of the investigator could affect completion of the trial
- Pump therapy before pregnancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site
Heliodor Swiecicki Clinical Gynecology and Obstetrics Hospital of Poznan University of Medical Sciences
Poznan, Wielkopolska, 60-535
Ewa Wender-Ozegowska, Prof. MD PhD, +48 (61) 841-93-02, ewozegow@ump.edu.pl
Ewa Wender-Ozegowska, Prof. MD PhD
About this study
This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. The primary objective is to measure the percentage of time spent in the target pregnancy glucose range (63-140 mg/dL). Secondary outcomes track mean glucose, HbA1c, and overall maternal and neonatal health to ensure safety and efficacy.
Read the detailed description
This study will evaluate the use of the MiniMed 780G insulin pump system in pregnant women with type 2 diabetes. The aim is to assess whether this treatment can help participants achieve good glucose control during pregnancy and support favorable maternal and neonatal outcomes.
This is a single-arm interventional study. All participants will use the same insulin pump and continuous glucose monitoring system from recruitment until delivery. The study will include pregnant women with type 2 diabetes who enter the study at 16 weeks of pregnancy or less.
Participants will attend regular follow-up visits during pregnancy. Researchers will review glucose data, adjust insulin treatment, measure HbA1c, and assess pregnancy and neonatal outcomes.
The main outcome is the percentage of time spent in the pregnancy target glucose range of 63 to 140 mg/dL from recruitment until delivery. The study will also assess mean glucose levels, maternal outcomes, and neonatal outcomes.
This study will evaluate the use of the MiniMed 780G insulin pump system in pregnant women with type 2 diabetes. The aim is to assess whether this treatment can help participants achieve good glucose control during pregnancy and support favorable maternal and neonatal outcomes.
This is a single-arm interventional study. All participants will use the same insulin pump and continuous glucose monitoring system from recruitment until delivery. The study will include pregnant women with type 2 diabetes who enter the study at 16 weeks of pregnancy or less.
Participants will attend regular follow-up visits during pregnancy. Researchers will review glucose data, adjust insulin treatment, measure HbA1c, and assess pregnancy and neonatal outcomes.
The main outcome is the percentage of time spent in the pregnancy target glucose range of 63 to 140 mg/dL from recruitment until delivery. The study will also assess mean glucose levels, maternal outcomes, and neonatal outcomes.
- Conditions
- Pregnancy, Type 2 Diabetes
- Being tested
- Automated insulin delivery system - Medtronic 780G
- Keywords
- type 2 diabetes, pregnancy, insulin pump, Automated insulin delivery system
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Automated insulin delivery system - Medtronic 780GDevice
Use of automated insulin delivery system in pregnant patients with type 2 diabetes
| Study group | Role | What they receive |
|---|---|---|
| Type 2 diabetes | Experimental | Pregnant patients with type 2 diabetes treated with automated insulin delivery system Receives: Device: Automated insulin delivery system - Medtronic 780G |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: From enrollment to the delivery
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Measured: From enrollment to the delivery
Secondary outcomes (76)
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: Week 18
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: Week 22
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: Week 26
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: Week 30
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: Week 34
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: Week 37
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Measured: Week 18
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Measured: Week 22
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Measured: Week 26
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Measured: Week 30
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Measured: Week 34
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Measured: Week 37
Change in the time in range values
Change in percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Measured: From the recruitment to delivery
Time above range
Percentage of time spent above target glucose values - >140 mg/dL (>7.8 mmol/L)
Measured: Week 18
Time above range
Percentage of time spent above target glucose values - >140 mg/dL (>7.8 mmol/L)
Measured: Week 22
Time above range
Percentage of time spent above target glucose values - >140 mg/dL (>7.8 mmol/L)
Measured: Week 26
Time above range
Percentage of time spent above target glucose values - >140 mg/dL (>7.8 mmol/L)
Measured: Week 30
Time above range
Percentage of time spent above target glucose values - >140 mg/dL (>7.8 mmol/L)
Measured: Week 34
Time above range
Percentage of time spent above target glucose values - >140 mg/dL (>7.8 mmol/L)
Measured: Week 37
Time above tight range
Percentage of time spent above target glucose values - >120 mg/dL (>6.7 mmol/L)
Measured: Week 18
Time above tight range
Percentage of time spent above target glucose values - >120 mg/dL (>6.7 mmol/L)
Measured: Week 22
Time above tight range
Percentage of time spent above target glucose values - >120 mg/dL (>6.7 mmol/L)
Measured: Week 26
Time above tight range
Percentage of time spent above target glucose values - >120 mg/dL (>6.7 mmol/L)
Measured: Week 30
Time above tight range
Percentage of time spent above target glucose values - >120 mg/dL (>6.7 mmol/L)
Measured: Week 34
Time above tight range
Percentage of time spent above target glucose values - >120 mg/dL (>6.7 mmol/L)
Measured: Week 37
Time below range
Percentage of time spent below target glucose values - <63 mg/dL (<3.5 mmol/L)
Measured: Week 18
Time below range
Percentage of time spent below target glucose values - <63 mg/dL (<3.5 mmol/L)
Measured: Week 22
Time below range
Percentage of time spent below target glucose values - <63 mg/dL (<3.5 mmol/L)
Measured: Week 26
Time below range
Percentage of time spent below target glucose values - <63 mg/dL (<3.5 mmol/L)
Measured: Week 30
Time below range
Percentage of time spent below target glucose values - <63 mg/dL (<3.5 mmol/L)
Measured: Week 34
Time below range
Percentage of time spent below target glucose values - <63 mg/dL (<3.5 mmol/L)
Measured: Week 37
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Measured: Week 18
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Measured: Week 22
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Measured: Week 26
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Measured: Week 30
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Measured: Week 34
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Measured: Week 37
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Measured: Week 18
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Measured: Week 22
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Measured: Week 26
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Measured: Week 30
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Measured: Week 34
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Measured: Week 37
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Measured: Week 18
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Measured: Week 22
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Measured: Week 26
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Measured: Week 30
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Measured: Week 34
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Measured: Week 37
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Measured: Week 18
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Measured: Week 22
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Measured: Week 26
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Measured: Week 30
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Measured: Week 34
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Measured: Week 37
Severe hypoglycemia episodes
Number of episodes of self-reported severe hypoglycemia.
Measured: From recruitment until delivery.
Gestational weight gain
Maternal gestational weight gain (kg)
Measured: From recruitment until delivery
Gestational weight gain from pre-pregnancy
Self-reported maternal gestational weight gain (kg)
Measured: From pre-pregnancy until delivery
Pregnancy hypertensive disorders
Preeclampsia, Eclampsia, Gestational hypertension
Measured: From recruitment until delivery
The mode of delivery
Vaginal, c-section, spontaneous, induction of labor
Measured: At delivery
Birth trauma
IADPSG criteria
Measured: At delivery
Gestational birth weight
Neonatal birth weight in grams
Measured: At delivery
Macrosomia
Gestational birth weight >4200g
Measured: At delivery
Large-for-gestational-age (LGA)
Neonatal birth weight >90th percentile
Measured: At delivery
Small-for-gestational-age (SGA)
Neonatal birth weight >10th percentile
Measured: At delivery
Placental weight
Measured in grams
Measured: At delivery
Gestational age
Timing of delivery
Measured: At delivery
Preterm birth
<37 weeks
Measured: At delivery
Number of neonates with respiratory distress syndrome
Defined as the number of neonates diagnosed with respiratory distress syndrome during the postnatal hospital stay, based on clinical signs of respiratory distress and the need for respiratory support, with or without radiological confirmation, according to local neonatal clinical practice.
Measured: From delivery until hospital discharge, assessed up to 20 weeks postpartum
Number of neonates with jaundice requiring phototherapy
Defined as the number of neonates diagnosed with neonatal jaundice requiring phototherapy during the postnatal hospital stay. Phototherapy requirement will be determined according to local neonatal clinical practice based on serum or transcutaneous bilirubin assessment.
Measured: From delivery until hospital discharge, assessed up to 20 weeks postpartum
Number of neonates with neonatal hypoglycemia
Neonatal hypoglycemia - glucose concentrations in neonatal blood <40 mg/dL (2.2 mmol/L) in a single laboratory measurement at least 3 hours after birth, in the first 24 hours of life
Measured: Assessed from delivery until 24 hours postpartum
Stillbirth
Pregnancy loss after 22 weeks
Measured: From week 22
Neonatal length of hospital stay
Duration of neonatal hospitalization, measured in days
Measured: From date of delivery until the date of hospital discharge, assessed up to 20 weeks
Length of stay in the neonatal intensive care unit (NICU)
Duration of NICU stay, measured in days
Measured: From date of NICU admission until the date of NICU discharge, assessed up to 20 weeks
Neonatal acidosis
Umbilical pH <7.15
Measured: At delivery
Apgar score
Apgar score <8
Measured: At delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start1 May 2026 (estimated)
- Primary completionOct 2028 (estimated)
- Study completionFeb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single group longitudinal observational design
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Poznan University of Medical Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- Medtronic
- Responsible party
- Sponsor
- Investigators
- Ewa Wender-Ozegowska, Prof. MD PhD, Principal investigator, Poznan University of Medical Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07602036
- Sponsor's protocol ID
- 599_25
- Acronym
- pUMPreg2
- Status last verified
- May 2026
- First submitted
- 6 May 2026
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Gladych-Macioszek A, Mantaj U, Tobola-Wrobel K, Radzicka-Mularczyk S, Sibiak R, Adamczak L, Desoye G, Wender-Ozegowska E. Early gestational diabetes mellitus and type 2 diabetes: do they differ in perinatal outcome- a retrospective analysis. BMC Pregnancy Childbirth. 2026 Mar 11;26(1):423. doi: 10.1186/s12884-026-08927-3.
PubMed 41807957Sibiak R, Iciek R, Gastolek K, Chudzynska E, Meek C, Wender-Ozegowska E. Ten-year national trends in the prevalence and outcomes of gestational diabetes mellitus in Poland: a population-based study. Pol Arch Intern Med. 2026 Feb 26;136(2):17202. doi: 10.20452/pamw.17202. Epub 2026 Jan 19.
PubMed 41562177
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Type 2 Diabetes and Pregnancy a Single-arm Interventional Study
- ClinicalTrials.gov ID
- NCT07602036
- Acronym / sponsor ID
- pUMPreg2 / 599_25
- Conditions
- Pregnancy, Type 2 Diabetes
- Keywords
- type 2 diabetes, pregnancy, insulin pump, Automated insulin delivery system
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Poznan University of Medical SciencesUniversity, hospital or other
- Collaborators
- Medtronic
- Study start
- 1 May 2026 (estimated)
- Primary completion
- Oct 2028 (estimated)
- Study completion
- Feb 2029 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. The primary objective is to measure the percentage of time spent in the target pregnancy glucose range (63-140 mg/dL). Secondary outcomes track mean glucose, HbA1c, and overall maternal and neonatal health to ensure safety and efficacy.
Detailed description
This study will evaluate the use of the MiniMed 780G insulin pump system in pregnant women with type 2 diabetes. The aim is to assess whether this treatment can help participants achieve good glucose control during pregnancy and support favorable maternal and neonatal outcomes.
This is a single-arm interventional study. All participants will use the same insulin pump and continuous glucose monitoring system from recruitment until delivery. The study will include pregnant women with type 2 diabetes who enter the study at 16 weeks of pregnancy or less.
Participants will attend regular follow-up visits during pregnancy. Researchers will review glucose data, adjust insulin treatment, measure HbA1c, and assess pregnancy and neonatal outcomes.
The main outcome is the percentage of time spent in the pregnancy target glucose range of 63 to 140 mg/dL from recruitment until delivery. The study will also assess mean glucose levels, maternal outcomes, and neonatal outcomes.
This study will evaluate the use of the MiniMed 780G insulin pump system in pregnant women with type 2 diabetes. The aim is to assess whether this treatment can help participants achieve good glucose control during pregnancy and support favorable maternal and neonatal outcomes.
This is a single-arm interventional study. All participants will use the same insulin pump and continuous glucose monitoring system from recruitment until delivery. The study will include pregnant women with type 2 diabetes who enter the study at 16 weeks of pregnancy or less.
Participants will attend regular follow-up visits during pregnancy. Researchers will review glucose data, adjust insulin treatment, measure HbA1c, and assess pregnancy and neonatal outcomes.
The main outcome is the percentage of time spent in the pregnancy target glucose range of 63 to 140 mg/dL from recruitment until delivery. The study will also assess mean glucose levels, maternal outcomes, and neonatal outcomes.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single group longitudinal observational design
| Arm | Type | Receives |
|---|---|---|
| Type 2 diabetes | Experimental | Device: Automated insulin delivery system - Medtronic 780GPregnant patients with type 2 diabetes treated with automated insulin delivery system |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Women with diagnosed pregestational type 2 diabetes or HbA1c >6.5% in the 1st trimester (ADA, PTD)
- Age 18-45 years
- Gestational age of 16 weeks +0 days or less at baseline
- Singleton pregnancy
- HbA1c at baseline 5.0-10%
Key exclusion criteria (4 listed)
- Other types of diabetes including T1D and Monogenic diabetes
- Major fetal congenital defects
- Severe nephropathy, psychiatric illness or other serious medical disorder that in the judgment of the investigator could affect completion of the trial
- Pump therapy before pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Automated insulin delivery system - Medtronic 780GUse of automated insulin delivery system in pregnant patients with type 2 diabetes | Device | Type 2 diabetes |
Primary outcome
Time in range
Time frame: From enrollment to the delivery
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Mean sensor glycemia
Time frame: From enrollment to the delivery
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
76 secondary outcomes
Time in range
Time frame: Week 18
Time in range
Time frame: Week 22
Time in range
Time frame: Week 26
Time in range
Time frame: Week 30
Time in range
Time frame: Week 34
Time in range
Time frame: Week 37
Time in tight range
Time frame: Week 18
Time in tight range
Time frame: Week 22
Time in tight range
Time frame: Week 26
Time in tight range
Time frame: Week 30
Time in tight range
Time frame: Week 34
Time in tight range
Time frame: Week 37
Change in the time in range values
Time frame: From the recruitment to delivery
Time above range
Time frame: Week 18
Time above range
Time frame: Week 22
Time above range
Time frame: Week 26
Time above range
Time frame: Week 30
Time above range
Time frame: Week 34
Time above range
Time frame: Week 37
Time above tight range
Time frame: Week 18
Time above tight range
Time frame: Week 22
Time above tight range
Time frame: Week 26
Time above tight range
Time frame: Week 30
Time above tight range
Time frame: Week 34
Time above tight range
Time frame: Week 37
Time below range
Time frame: Week 18
Time below range
Time frame: Week 22
Time below range
Time frame: Week 26
Time below range
Time frame: Week 30
Time below range
Time frame: Week 34
Time below range
Time frame: Week 37
Mean sensor glycemia
Time frame: Week 18
Mean sensor glycemia
Time frame: Week 22
Mean sensor glycemia
Time frame: Week 26
Mean sensor glycemia
Time frame: Week 30
Mean sensor glycemia
Time frame: Week 34
Mean sensor glycemia
Time frame: Week 37
Coefficient of variation (%CV)
Time frame: Week 18
Coefficient of variation (%CV)
Time frame: Week 22
Coefficient of variation (%CV)
Time frame: Week 26
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Background: PubMed 41807957Gladych-Macioszek A, Mantaj U, Tobola-Wrobel K, Radzicka-Mularczyk S, Sibiak R, Adamczak L, Desoye G, Wender-Ozegowska E. Early gestational diabetes mellitus and type 2 diabetes: do they differ in perinatal outcome- a retrospective analysis. BMC Pregnancy Childbirth. 2026 Mar 11;26(1):423. doi: 10.1186/s12884-026-08927-3.
- Background: PubMed 41562177Sibiak R, Iciek R, Gastolek K, Chudzynska E, Meek C, Wender-Ozegowska E. Ten-year national trends in the prevalence and outcomes of gestational diabetes mellitus in Poland: a population-based study. Pol Arch Intern Med. 2026 Feb 26;136(2):17202. doi: 10.20452/pamw.17202. Epub 2026 Jan 19.
- Individual participant dataSharing planned: No
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ewa Wender-Ozegowska, Prof. MD PhD principal investigator
Poznan University of Medical Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Automated insulin delivery system - Medtronic 780G in people with Pregnancy and Type 2 Diabetes, run by Poznan University of Medical Sciences at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ewa Wender-Ozegowska, Prof. MD PhD (+48 (61) 841-93-02, ewozegow@ump.edu.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time in range (time frame: From enrollment to the delivery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07602036, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.